Viridian Q3 net loss $76.7M; positive phase 3 TED data, VRDN-008 best-in-class NHP profile

Viridian Therapeutics, Inc.\DE

2024-Q3 EPS reported -$2.98 revenue$230,000

Q3 net loss $76.7M vs $47.7M YoY; cash $753.2M, net proceeds $243.2M from Sep offering; runway into H2 2027.
Positive phase 3 THRIVE data for veligrotug in active TED; THRIVE-2 topline expected Dec 2024.
Initiated phase 3 REVEAL-1 and REVEAL-2 for VRDN-003; topline data anticipated H1 2026.
VRDN-008 NHP data: 3x half-life vs efgartigimod, 20% deeper IgG reduction; IND planned year-end 2025.
VRDN-006 IND submission by year-end 2024; proof-of-concept IgG reduction data in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.